Efficacy and safety of abrocitinib in elderly Chinese patients with moderate-to-severe AD: a single-center, retrospective study

Supplemental data of abrocitinib improves both physician- and patient-reported outcomes in elderly Chinese patients with moderate-to-severe AD. Figure S1. Abrocitinib improves both physician- and patient-reported outcomes in elderly Chinese patients with moderate-to-severe AD. (a) Distribution of Investigator’s Global Assessment (IGA) scores at baseline (BL) and last visit (LV), and 85.7% of patients achieved IGA score of 0 or 1; (b) The median EASI score improved from 20.6 [15.3, 31.7] at BL to 3.6 [2.0, 5.7] at LV; (c) Peak Pruritus Numerical Rating Scale (PP-NRS) scores decreased from 8 [7, 9] at BL to 2 [1, 3] at LV; (d) Dermatology Life Quality Index (DLQI) scores improved from 16.5 [13.3, 19.8] at BL to 4 [2, 5] at LV. IGA response proportions were compared using the Chi-square test for trend. Changes in EASI, PP-NRS, and DLQI scores from BL to lV were analyzed using the Wilcoxon signed-rank test. ****P < 0.0001. sTable1. Clinical outcomes in moderate-to-severe elderly Chinese AD patients treated with abrocitinib.阿布昔替尼（abrocitinib）的补充数据可改善中国老年中重度特应性皮炎（Atopic Dermatitis，AD）患者的医师报告结局与患者自我报告结局。 补充图S1：阿布昔替尼可改善中国老年中重度特应性皮炎患者的医师与患者报告结局。(a) 基线（BL）与末次访视（LV）时的研究者总体评估（Investigator’s Global Assessment，IGA）评分分布，85.7%的患者IGA评分达到0或1；(b) 湿疹面积与严重程度指数（Eczema Area and Severity Index，EASI）的中位数评分从基线时的20.6 [15.3, 31.7] 改善至末次访视时的3.6 [2.0, 5.7]；(c) 峰值瘙痒数字评定量表（Peak Pruritus Numerical Rating Scale，PP-NRS）评分从基线时的8 [7, 9] 降至末次访视时的2 [1, 3]；(d) 皮肤病生活质量指数（Dermatology Life Quality Index，DLQI）评分从基线时的16.5 [13.3, 19.8] 改善至末次访视时的4 [2, 5]。 采用趋势卡方检验比较IGA应答率的组间差异；采用Wilcoxon符号秩检验分析基线至末次访视时EASI、PP-NRS及DLQI评分的变化。****P < 0.0001。 补充表1：接受阿布昔替尼治疗的中国老年中重度特应性皮炎患者的临床结局。